ClinicalTrials.gg

Program

MK-8591A

A development code.

Its studies are led by Merck.

Furthest: phase 3, since Feb 26, 20212 company-led studies, 1 open or runningNext primary completion: May 29, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck21 open or runningphase 3since Feb 26, 2021Feb 26, 2021May 29, 2029phase 3 · NCT04776252
  • Named in Merck’s own pipeline as islatravir + lenacapavir (MK-8591D), phase 3, as of Nov 2, 2026 (source).
  • Named in Merck’s own pipeline as islatravir + ulonivirine (MK-8591B), phase 2, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 26, 2021First study: phase 3 study in HIV-1 InfectionFirst studyNCT04776252 · 2,000 enrolled · United States, Australia, Canada and more
  2. Dec 2, 2024Phase 1 study in HealthyNCT06719570 · 24 enrolled · United States

Ahead

  1. May 29, 2029Primary completion: phase 3 study in HIV-1 InfectionNCT04776252

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06719570Healthy · United States1CompletedMar 15, 202424
NCT04776252HIV-1 Infection · United States, Australia, Canada and more3Active, not recruitingMay 29, 20292,000

How it is read

Names in the registry

  • “MK-8591A”, 2 entries

Codes read as this program: MK8591A.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.